ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.6300
-0.0600 (-1.63%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.6900
Open3.7000
Bid0.0000 x 3200
Ask0.0000 x 900
Day's Range3.5700 - 3.7000
52 Week Range2.0800 - 6.9600
Volume561,495
Avg. Volume1,442,139
Market Cap215.324M
Beta (3Y Monthly)3.33
PE Ratio (TTM)N/A
EPS (TTM)-1.3420
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.94
Trade prices are not sourced from all markets
  • GuruFocus.com8 days ago

    ADMA Biologics: Selloff Creates Buying Opportunity

    The fundamental growth story is intact

  • PR Newswire20 days ago

    SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ADMA Biologics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

    NEW YORK , June 6, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...

  • GuruFocus.com27 days ago

    ADMA Biologics Is De-Risked and Ready to Rise

    After years of struggle, ADMA Biologics (ADMA) appears at last to be poised for bigger things. The Food and Drug Administration's recent approval of two of its intravenous immune globulin (IVIG) drug products, Asceniv and Bivigam, has put this stock back on the radar. Combined with a timely capital raise, ADMA's two new products should set it up for an impressive breakout in the second half of 2019.

  • GlobeNewswire28 days ago

    ADMA Biologics to Present at Upcoming Investor Conferences

    Jefferies 2019 Healthcare Conference Raymond James Life Sciences and MedTech Conference RAMSEY, N.J. and BOCA RATON, Fla., May 29, 2019 -- ADMA Biologics, Inc. (NASDAQ:.

  • TheStreet.comlast month

    These 3 Biotech Stocks Are Attracting Insider Buying

    Volatility continues to pick up as trade tensions between the U.S. and China continue to escalate with no current end in sight. Add in EU elections and the coming departure of the prime minister in the U.

  • GlobeNewswirelast month

    ADMA Biologics Announces Closing of $51.75 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today the closing of its previously announced underwritten public offering of 12,937,500 shares of its common stock at a public offering price of $4.00 per share, including 1,687,500 shares of common stock issued upon the exercise in full of the underwriters’ option to purchase additional shares. The gross proceeds from the offering are $51.75 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

  • GuruFocus.comlast month

    Adma Biologics Inc (ADMA) President and CEO Adam S Grossman Bought $120,000 of Shares

    President and CEO of Adma Biologics Inc (NASDAQ:ADMA) Adam S Grossman bought 30,000 shares of ADMA on 05/17/2019 at an average price of $4 a share.

  • GlobeNewswirelast month

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced that it has designated four experienced executives from the biotechnology industry for its board of directors (the “Board”), including Dov A. Goldstein, M.D., M.B.A., Diego Miralles, M.D., Franklyn Prendergast, M.D., Ph.D., and Eric Richman, M.B.A, to become effective upon the closing of the Company’s merger with Ohr Pharmaceutical, Inc. (OHRP) (“Ohr”). The four designees, together with Dietrich A. Stephan, Ph.D., chairman and chief executive officer of the company, will comprise the entire board of directors for the combined company.

  • GlobeNewswirelast month

    ADMA Biologics Announces Proposed $45 Million Public Offering of Common Stock

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”) a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announced today that it has commenced a $45 million underwritten public offering of its common stock. The Company intends to grant the underwriter of the offering a 30-day option to purchase up to an additional 15 percent of the number of shares of common stock sold in connection with the offering. Jefferies LLC is acting as sole book-running manager of the proposed offering.

  • GlobeNewswire2 months ago

    FDA Approves Prior Approval Supplement for BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., May 10, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • Associated Press2 months ago

    Adma Biologics: 1Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring gains, came to 31 cents per share. The results topped Wall Street expectations. The average ...

  • GlobeNewswire2 months ago

    ADMA Biologics Reports First Quarter 2019 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., May 08, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.

  • GlobeNewswire2 months ago

    ADMA Biologics Granted U.S. Patent for Treatment and Prevention of Pneumococcal Infections

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), today announced that the United States Patent and Trademark Office issued to the Company U.S. Patent No. 10,259,865 related to methods of treatment and prevention of S. pneumonia infection.  The patent claims encompass methods of preparing immune globulin via harvesting plasma from S. pneumonia vaccinated, healthy adult human donors and pooling the harvested plasma as the source for manufacturing a hyperimmune anti-pneumococcal immune globulin containing elevated opsonic antibodies to a plurality of S. pneumonia serotypes. The issued claims also encompass hyperimmune anti-pneumococcal immune globulin so prepared, methods of treating S. pneumonia infection and methods of providing immunotherapy using the hyperimmune anti-pneumococcal immune globulin.

  • ADMA Biologics: Wall Street Projects Robust Revenue Growth
    Market Realist3 months ago

    ADMA Biologics: Wall Street Projects Robust Revenue Growth

    Why ADMA Biologics Stock Soared Yesterday(Continued from Prior Part)Revenue growth estimates ADMA Biologics (ADMA) has two commercialized assets in its portfolio, Nabi-HB and BIVIGAM, which it added through the acquisition of assets from Biotest

  • Why ADMA Biologics Stock Soared Yesterday
    Market Realist3 months ago

    Why ADMA Biologics Stock Soared Yesterday

    Why ADMA Biologics Stock Soared YesterdayShare price movements Yesterday, ADMA Biologics (ADMA) closed at $5.06, which is about 24.32% higher than its previous closing price, 143.27% higher than its 52-week low of $2.08, and 27.30% lower than its

  • Benzinga3 months ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • GlobeNewswire3 months ago

    ADMA Receives Department of Health and Human Services U.S. License

    ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that the U.S. Food and Drug Administration (“FDA”) has issued a Department of Health and Human Services U.S. license No. 2019 to the Company in connection with the approval of ASCENIV™ Immune Globulin Intravenous, Human – slra 10% Liquid.

  • Benzinga3 months ago

    ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

    ADMA announced Monday after the market close that the FDA approved its Asceniv, a novel, patented, intravenous immunoglobulin product for the treatment of primary humoral immunodeficiency disease, or PIDD, in adults and adolescents ages 12-17. PIDD is a collective name for more than 300 diseases that occur due to defects in the body's immune system, invariably manifesting as acute or recurrent infections. Asceniv is manufactured using ADMA's unique, patented plasma donor screening methodology and tailored plasma pooling design, which blends the source plasma and plasma from donors testing using its proprietary microneutralization assay.

  • MarketWatch3 months ago

    ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

    Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday, after the biopharmaceutical company said its ASCENIV treatment of primary humoral immunodeficiency disease (PIDD) was approved by the Food and Drug Administration. Trading volume jumped to 3.6 million shares, compared with the full-day average of about 577,000 shares, and enough to make the stock the most actively traded before the open. ADMA said late Monday that expect to have ASCENIV available for commercial launch during the second half of 2019. "With the receipt of ASCENIV's™ FDA approval, ADMA, at its sole option, can elect to access up to an additional $27.5M of available funding from Perceptive Advisors under ADMA's existing credit facility," said Chief Executive Adam Grossman. The stock has soared 77.3% year to date through Monday, while the iShares Nasdaq Biotechnology ETF has rallied 16.1% and the S&P 500 has gained 14.4%.

  • Benzinga3 months ago

    The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...

  • GlobeNewswire3 months ago

    FDA Approves ASCENIV™, a Novel Intravenous Immune Globulin

    Approved for Use in the Treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in Adults and Adolescents (12 to 17 Years of Age)FDA Approval Triggers Funding up.

  • Associated Press3 months ago

    Adma Biologics: 4Q Earnings Snapshot

    The Ramsey, New Jersey-based company said it had a loss of 39 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire3 months ago

    ADMA Biologics Reports Full Year 2018 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., March 13, 2019 -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and.